The acquisition centers on Thymmune’s regenerative thymic cell therapy platform, which targets immunodeficiencies, autoimmune disorders, and post-transplant organ tolerance. The startup’s most advanced candidate, THY-100, remains in preclinical development for congenital athymia—a condition where infants lack a functional thymus, the organ responsible for maturing T-cells vital to immune health.

United Therapeutics Chief Executive Martine Rothblatt noted that the technology could address the root causes of numerous life-threatening conditions by restoring T-cell receptor diversity. For the acquiring company, the move serves a broader strategic objective: scaling the supply of transplantable organs while bolstering its existing portfolio of immunomodulatory treatments.